Sheffield cell therapy spinout Rinri secured corporate backing from Boehringer Ingelheim and UCB in a seed round that will drive work on stem cell-based treatments for hearing loss.

Rinri, a UK-based cell therapy spinout from University of Sheffield focused on tackling hearing loss, yesterday obtained £1.4m ($1.8m) in a seed round co-led by investment vehicles for pharmaceutical firms Boehringer Ingelheim and UCB.
Science incubator BioCity participated in the round, with Boehringer Ingelheim and UCB investing through their respective corporate venturing subsidiaries Boehringer Ingelheim Venture Fund (BIVF) and UCB Ventures.
Founded in 2018, Rinri is advancing stem cell-based treatments to restore hearing that has been impaired by…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?